Clinical trials: Pathologic Neovascularization
Corneal Neovascularization, Corneal Graft Failure
Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
The purpose of the study is to test the investigational drug Gamunex-C on the growth of blood vessels over the cornea. This study is being conducted by Dr. Balamurali Ambati at the Moran Eye Center at the University of Utah.
- Conditions
- Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
- Trial name
- NCT02042027
- Testing
- Gamunex-C
- Where
- United States
- Sponsor
- University of Utah
Age Related Macular Degeneration (AMD), Macular Degeneration
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established…
- Conditions
- Age Related Macular Degeneration (AMD), Macular Degeneration, Choroidal Neovascularization (CNV)
- Trial name
- PERSPECTIVES (NCT00327470)
- Testing
- Pegaptanib Sodium 0.3 mg
- Where
- 58 sites in Austria, Belgium and 13 more
- Volunteers
- 288 people
- Sponsor
- Pfizer
Pathological Myopic Choroidal Neovascularization
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV
- Trial name
- NCT04922151
- Testing
- 601, Ranibizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Neovascular Age Related Macular Degeneration
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
Neovascular age-related macular degeneration (nAMD) is characterized by the presence of choroidal neovascularization (CNV). Choroidal neovascularization consists of abnormal blood vessels originating from the choroid and can lead…
- Trial name
- OCTOPUS (NCT04239027)
- Testing
- RTH258/Brolucizumab
- Where
- 40 sites in France
- Volunteers
- 210 people
- Sponsor
- Novartis Pharmaceuticals
Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.
- Trial name
- VAULT (NCT01950741)
- Testing
- aflibercept
- Where
- 8 sites in South Korea
- Volunteers
- 48 people
- Sponsor
- Pusan National University Hospital
Peripheral Artery Disease, Severe Intermittent Claudication
Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain)
The goal of the study is to determine the safety and possible effectiveness of various doses of autologous (one's own) stem cells, delivered with a needle into the regions of the leg with poor blood flow in patients with blocked…
- Trial name
- NCT00311805
- Testing
- Autologous Stem Cells (CD34+)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Losordo, Douglas, M.D.
Macular Degeneration, Choroidal Neovascularization
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
The study will investigate the safety and feasibility of using the TheraSight(TM) Brachytherapy System for treatment of wet age-related macular degeneration (AMD).
- Trial name
- NCT00100087
- Testing
- Ocular Brachytherapy
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Theragenics Corporation
Polypoidal Choroidal Vasculopathy
Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen
The aim of this study is to compare the outcomes of different treatment methods including photodynamic therapy (PDT), intravitreal ranibizumab injection (IVR) and combination therapy under the "1+PRN" treatment regimen for…
- Trial name
- NCT03459144
- Testing
- verteporfin, verteporfin and ranibizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Age-related Macular Degeneration
Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)
The purpose of the study was to compare 2 treatment regimens for patients suffering from choroidal neovascularisation secondary to age-related macular degeneration (AMD).
- Trial name
- SALUTE (NCT01148511)
- Testing
- Ranibizumab 0.5 mg
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 99 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Neovascularization, Age Related Macular Degeneration
Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD
The purpose of the study is to detect persisting or early new activity of choroidal neovascularization (CNV) due to age related macular degeneration (AMD) during the first 12 months following the first ranibizumab dose at…
- Trial name
- NCT03393767
- Testing
- Ranibizumab
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Vista Klinik
Exudative Age-related Macular Degeneration
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD).
- Trial name
- Nexus (NCT01414153)
- Testing
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- Where
- 44 sites in United States
- Volunteers
- 158 people
- Sponsor
- Lpath, Inc.
Age-related Macular Degeneration
Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration
The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).
- Trial name
- NCT01835015
- Testing
- CLG561
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Corneal Neovascularization
Photodynamic Therapy With Verteporfin for Corneal Neovascularization
Purpose: To investigate the efficacy of photodynamic therapy with verteporfin for the treatment of patients with corneal neovascularization. Design: Prospective, non-comparative case series.
- Trial name
- NCT00471406
- Testing
- Photodynamic Therapy with Verteporfin
- Sponsor
- Chonnam National University Hospital
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
- Trial name
- NCT04645212
- Testing
- ADVM-022
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Adverum Biotechnologies, Inc.
Age-related Macular Degeneration
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina.
- Trial name
- NCT00539734
- Testing
- ranibizumab
- Where
- Thailand
- Volunteers
- 25 people
- Sponsor
- Prince of Songkla University
Polypoidal Choroidal Vasculopathy
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
1. Primary objectives a. To evaluate the Effects of intravitreal Bevacizumab on polypoidal choroidal vasculopathy(PCV) 2. Secondary objectives 1. To assess the changes in visual acuity 2.
- Trial name
- NCT00383812
- Testing
- Intravitreal Bevacizumab
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Asan Medical Center
Idiopathic Choroidal Neovascularization
Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients
After myopia, the second etiology of choroidal neovascularization (CNV) in young adults (<50 years old) is idiopathic choroidal neovascularization (ICNV) whose etiology remains unknown.
- Trial name
- INTUITION (NCT02257502)
- Testing
- aflibercept
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Age Related Macular Degeneration
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
This study is an evaluation of the short term effects on CNV perfusion of a same-day administration of photodynamic therapy (PDT) with Visudyne® and an intravitreal injection of Lucentis® (ranibizumab, 0.3 mg).
- Trial name
- NCT00413829
- Testing
- Intravitreal ranibizumab with photodynamic therapy
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Age-related Macular Degeneration
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
- Trial name
- NCT02214628
- Testing
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Where
- 13 sites in United States
- Volunteers
- 101 people
- Sponsor
- Ophthotech Corporation
Retinal Pigment Epithelial Detachment
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
- Trial name
- NCT00749021
- Testing
- Ranibizumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Clement K. Chan